Mayne Pharma Group Limited (MYX.AX)
AUD 7.02
(0.57%)
AUD 7.02
(0.57%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 388.15 Million AUD | 111.43% |
| 2023 | 183.58 Million AUD | 16.82% |
| 2022 | 157.14 Million AUD | -60.79% |
| 2021 | 400.78 Million AUD | -12.3% |
| 2020 | 456.98 Million AUD | -12.99% |
| 2019 | 525.2 Million AUD | -0.96% |
| 2018 | 530.31 Million AUD | -7.38% |
| 2017 | 572.59 Million AUD | 114.23% |
| 2016 | 267.27 Million AUD | 90.47% |
| 2015 | 140.32 Million AUD | -1.31% |
| 2014 | 142.18 Million AUD | 72.84% |
| 2013 | 82.26 Million AUD | 61.05% |
| 2012 | 51.07 Million AUD | 4.74% |
| 2011 | 48.76 Million AUD | 31.65% |
| 2010 | 37.04 Million AUD | 3462.33% |
| 2009 | 1.03 Million AUD | 26.69% |
| 2008 | 820.81 Thousand AUD | 485.83% |
| 2007 | 140.11 Thousand AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 200.47 Million AUD | 0.0% |
| 2024 Q2 | 187.92 Million AUD | 0.0% |
| 2024 FY | 388.39 Million AUD | 111.56% |
| 2023 FY | 183.58 Million AUD | 16.82% |
| 2023 Q2 | 101.16 Million AUD | 0.0% |
| 2023 Q4 | 82.42 Million AUD | 0.0% |
| 2022 Q2 | 196.43 Million AUD | 0.0% |
| 2022 FY | 157.14 Million AUD | -60.79% |
| 2022 Q4 | 228.36 Million AUD | 0.0% |
| 2021 Q2 | 208.84 Million AUD | 0.0% |
| 2021 Q4 | 191.93 Million AUD | 0.0% |
| 2021 FY | 400.78 Million AUD | -12.3% |
| 2020 FY | 456.98 Million AUD | -12.99% |
| 2020 Q2 | 227.15 Million AUD | 0.0% |
| 2020 Q4 | 229.83 Million AUD | 0.0% |
| 2019 Q4 | 250.83 Million AUD | 0.0% |
| 2019 FY | 525.2 Million AUD | -0.96% |
| 2019 Q2 | 274.37 Million AUD | 0.0% |
| 2018 Q2 | 243.25 Million AUD | 0.0% |
| 2018 FY | 530.31 Million AUD | -7.38% |
| 2018 Q4 | 287.05 Million AUD | 0.0% |
| 2017 Q2 | 294.83 Million AUD | 0.0% |
| 2017 Q4 | 277.76 Million AUD | 0.0% |
| 2017 FY | 572.59 Million AUD | 114.23% |
| 2016 FY | 267.27 Million AUD | 90.47% |
| 2016 Q4 | 140.01 Million AUD | 0.0% |
| 2016 Q2 | 127.26 Million AUD | 0.0% |
| 2015 Q4 | 81.87 Million AUD | 0.0% |
| 2015 Q2 | 59.54 Million AUD | 0.0% |
| 2015 FY | 140.32 Million AUD | -1.31% |
| 2014 Q2 | 69.95 Million AUD | 0.0% |
| 2014 FY | 142.18 Million AUD | 72.84% |
| 2014 Q4 | 73.29 Million AUD | 0.0% |
| 2013 Q4 | 56.25 Million AUD | 173.53% |
| 2013 Q3 | 20.56 Million AUD | -24.33% |
| 2013 Q2 | 27.17 Million AUD | 0.0% |
| 2013 FY | 82.26 Million AUD | 61.05% |
| 2012 Q2 | 12.72 Million AUD | 4.93% |
| 2012 Q3 | 12.72 Million AUD | 0.0% |
| 2012 Q4 | 12.72 Million AUD | 0.0% |
| 2012 FY | 51.07 Million AUD | 4.74% |
| 2012 Q1 | 12.12 Million AUD | 0.0% |
| 2011 Q4 | 12.12 Million AUD | 0.0% |
| 2011 FY | 48.76 Million AUD | 31.65% |
| 2011 Q3 | 12.12 Million AUD | 0.0% |
| 2011 Q2 | 12.12 Million AUD | 36.91% |
| 2011 Q1 | 8.85 Million AUD | 0.0% |
| 2010 Q3 | 8.85 Million AUD | 0.0% |
| 2010 Q4 | 8.85 Million AUD | 0.0% |
| 2010 Q1 | 259.97 Thousand AUD | 0.0% |
| 2010 Q2 | 8.85 Million AUD | 3306.89% |
| 2010 FY | 37.04 Million AUD | 3462.33% |
| 2009 Q3 | 259.97 Thousand AUD | 0.0% |
| 2009 Q2 | 259.97 Thousand AUD | 26.69% |
| 2009 Q1 | 205.2 Thousand AUD | 0.0% |
| 2009 Q4 | 259.97 Thousand AUD | 0.0% |
| 2009 FY | 1.03 Million AUD | 26.69% |
| 2008 Q1 | 35.02 Thousand AUD | 0.0% |
| 2008 Q4 | 205.2 Thousand AUD | 0.0% |
| 2008 Q2 | 205.2 Thousand AUD | 485.83% |
| 2008 Q3 | 205.2 Thousand AUD | 0.0% |
| 2008 FY | 820.81 Thousand AUD | 485.83% |
| 2007 FY | 140.11 Thousand AUD | 0.0% |
| 2007 Q4 | 35.02 Thousand AUD | 0.0% |
| 2007 Q3 | 35.02 Thousand AUD | 0.0% |
| 2007 Q2 | 35.02 Thousand AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Firebrick Pharma Limited | 14.52 Thousand AUD | -2672748.093% |